What does A.forall Development do?
ALTER PHARMA specializes in the development and production of high-quality generic pharmaceuticals. The company focuses on providing accessible medication solutions across various therapeutic areas. With a commitment to innovation and compliance, ALTER PHARMA aims to enhance patient care through reliable pharmaceutical products.
- Sectors
- Holding companies
- Activities
- Signals
-
Reporting lossesReporting losses € -1.67M
The company reported a loss in the latest financial year.
Poor liquidityPoor liquidity 0.28The current ratio is below 1: may be insufficient to cover short-term debt.
Strong equityStrong equity € 37.59MStrong equity provides a buffer against setbacks.
Low riskLow risk 52.7%Good solvency (> 30%) points to long-term financial stability.
Positive cashflowPositive cashflow € 2.27MPositive operating cash flow in the latest financial year.
Positive EBITDAPositive EBITDA € 3.71MPositive EBITDA: operating activities are profitable.
Healthy social debtHealthy social debt 15.3%Social debts stay manageable relative to personnel costs.
- Investments
- Neogen 100%
Financial ratios
|
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
€
5.52M
|
€
5.25M
|
€
5.28M
|
€
2.42M
|
|
|
€
3.71M
|
€
3.39M
|
€
3.39M
|
€
335K
|
|
|
€
-1.67M
|
€
12.33M
|
€
2.23M
|
€
-599K
|
|
|
€
37.59M
|
€
39.26M
|
€
51.93M
|
€
49.70M
|
|
|
52.70%
|
64.18%
|
70.43%
|
74.89%
|
|
|
€
33.74M
|
€
21.91M
|
€
21.80M
|
€
16.66M
|
|
|
€
440K
|
€
1.11M
|
€
272K
|
€
466K
|
|
|
11
|
11
|
10.80
|
11.80
|
Publications 44
All publications- Ontslagen - Benoemingen 24/11/2025
- Ontslagen - Benoemingen 30/07/2024
- Statuten (Vertaling, Cordinatie, Overige Wijzigingen, ) - Benaming 11/01/2024
- Ontslagen - Benoemingen 27/01/2022
- Ontslagen - Benoemingen 25/10/2021
News
Show all- Belgium: Abacus Medicine Acquiring A.forall’s R&H Division Investors in Healthcare 1 year ago
- Riverside’s A.forall To Sell Retail And Hospital Division To Abacus Medicine pehub.com 1 year ago
- Why Court Battles Could Alter The Path Of Emergency Use Authorizations For Vaccines PharmExec 1 year ago
- Fda Weighs New Study Requirements For Sarepta To Confirm Safety Of Gene Therapy Elevidys: Report Fierce Pharma 1 year ago
- Bayer's Kerendia Wins Fda Label Expansion To Treat 2 Types Of Heart Failure Fierce Pharma 1 year ago
Frequently asked questions
Answers to the most common questions about A.forall Development, based on official government data and the filed annual accounts.
What is the VAT number of A.forall Development?
The VAT number of A.forall Development is BE0827.869.165.
How many employees work at A.forall Development?
In 2025, A.forall Development employed 11.00 full-time equivalents (FTE).
When was A.forall Development established?
A.forall Development was founded in 15-07-2010.
What is the official address of A.forall Development?
The official address of A.forall Development is Marie Curiesquare 50 Anderlecht 1070.
What is the legal form of A.forall Development?
The juridical form of A.forall Development is Public limited company (NV/SA).
What is the annual revenue of A.forall Development?
The 2025 accounts of A.forall Development do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.
What does A.forall Development do?
ALTER PHARMA specializes in the development and production of high-quality generic pharmaceuticals. The company focuses on providing accessible medication solutions across various therapeutic areas. With a commitment to innovation and compliance, ALTER PHARMA aims to enhance patient care through reliable pharmaceutical products.
Is A.forall Development a reliable company?
A.forall Development is a registered Rechtspersoon with company number 0827.869.165 and can be verified through the official CBE database.
What is the credit limit of A.forall Development?
The estimated credit limit of A.forall Development is €4,780,041.
Is A.forall Development still active?
A.forall Development currently has the status "Normal situation" and is active.